20/20 Biolabs, Inc. (AIDX)
NCM · Healthcare · Medical Devices
$0.44
-4.72%
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
Market Cap
$5.4M
Shares Outstanding
12.3M
P/S (TTM)
2.7x
Exchange
NCM
Currency
USD
About 20/20 Biolabs, Inc.
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
Quarterly Financials
| Metric | 2024-12-31 | 2025-03-31 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 536K | 554K | 538K | 353K |
| Gross Profit | 163K | 166K | 130K | 63K |
| Operating Income | -1.2M | -772K | -913K | -1.4M |
| Net Income | -1.2M | -765K | -1.3M | -2.2M |
| Diluted EPS | $nan | $-0.07 | $nan | $-0.28 |
Annual Financials
| Metric | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Revenue | 1.4M | 1.8M | 2.0M |
| Gross Profit | 109K | 360K | 605K |
| Operating Income | -6.4M | -5.7M | -3.3M |
| Net Income | -6.4M | -5.6M | -3.7M |
| Diluted EPS | $-0.62 | $-0.54 | $-0.36 |